GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (FRA:NKB2) » Definitions » Other Current Liabilities

TG Therapeutics (FRA:NKB2) Other Current Liabilities : €18.9 Mil (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is TG Therapeutics Other Current Liabilities?

TG Therapeutics's other current liabilities for the quarter that ended in Dec. 2024 was €18.9 Mil.

TG Therapeutics's quarterly other current liabilities increased from Jun. 2024 (€9.8 Mil) to Sep. 2024 (€12.1 Mil) and increased from Sep. 2024 (€12.1 Mil) to Dec. 2024 (€18.9 Mil).

TG Therapeutics's annual other current liabilities increased from Dec. 2022 (€9.1 Mil) to Dec. 2023 (€12.5 Mil) and increased from Dec. 2023 (€12.5 Mil) to Dec. 2024 (€18.9 Mil).


TG Therapeutics Other Current Liabilities Historical Data

The historical data trend for TG Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Other Current Liabilities Chart

TG Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.94 10.34 9.06 12.52 18.92

TG Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.52 7.05 9.77 12.06 18.92

TG Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.


TG Therapeutics Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


TG Therapeutics Business Description

Traded in Other Exchanges
Address
3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

TG Therapeutics Headlines

No Headlines